Brolucizumab in polypoidal choroidal vasculopathy
Expert Opin Biol Ther
.
2022 Jul;22(7):809-812.
doi: 10.1080/14712598.2022.2094239.
Epub 2022 Jun 27.
Authors
Ashish Sharma
1
,
Nikulaa Parachuri
2
,
Nilesh Kumar
3
,
Baruch D Kuppermann
4
,
Anat Loewenstein
5
,
Francesco Bandello
6
Affiliations
1
Lotus Eye Hospital and Institute, Coimbatore, India.
2
Department of Vitreoretina, Sankara Eye Hospital, Coimbatore, India.
3
Madhavi Netralaya, Ara, India.
4
Gavin Herbert Eye Institute, University of California, Irvine, CA, USA.
5
Division of Ophthalmology, Tel Aviv Medical, Tel Aviv University, Israel.
6
Scientific Institute San Raffaele, University Vita-Salute, Milano, Italy.
PMID:
35737884
DOI:
10.1080/14712598.2022.2094239
No abstract available
Keywords:
Brolucizumab; Efficacy; IPCV; Safety.
Publication types
Editorial
MeSH terms
Antibodies, Monoclonal, Humanized* / therapeutic use
Choroid
Humans
Retrospective Studies
Vascular Diseases*
Substances
Antibodies, Monoclonal, Humanized
brolucizumab